OKYO Pharma Limited Sponsored ADR OKYO

OKYO Pharma filed its annual report, reporting a strengthened cash position and accelerated Phase 3 development plans. Strengthened cash reserves directly enable faster Phase 3 progress and improve financial runway for OKYO.

OKYO Pharma files annual report, highlighting cash position and Phase 3 trial plans. Annual report filing discloses cash position and Phase 3 trial plans for OKYO.

OKYO Pharma advances toward Phase 3 FDA trial. Phase 3 trial advancement constitutes a major regulatory milestone capable of substantially altering company trajectory and investor sentiment.

OKYO Pharma received FDA feedback and will advance urcosimod into Phase 3 trials for neuropathic corneal pain. Phase 3 advancement after FDA feedback marks a major regulatory milestone that can drive clinical progress and investor interest.

OKYO Pharma received positive FDA Type D meeting feedback and is advancing Urcosimod into a global Phase 3 pivotal trial for neuropathic corneal pain. Positive FDA feedback and Phase 3 acceleration of lead asset materially de-risks development and can drive valuation gains.

OKYO Pharma clears key FDA milestone advancing toward Phase 3 trial for neuropathic corneal pain treatment. FDA milestone clearance advances OKYO toward Phase 3 trial in neuropathic corneal pain potentially boosting prospects significantly.

OKYO Pharma gains attention as a buy candidate on the strength of its ocular disease pipeline, upcoming clinical milestones and expanding market opportunity in dry eye and neuropathic pain treatments. Positive buy recommendation can lift near-term investor interest and trading volume but lacks concrete catalysts such as trial data or regulatory approval.

OKYO Pharma advances clinical strategy after Scientific Advisory Board (SAB) meeting and presentation at ASCRS conference. SAB meeting and ASCRS presentation mark significant clinical progress for OKYO's ophthalmology pipeline, boosting development momentum and investor interest.

OKYO Pharma announces Scientific Advisory Board meeting and Urcosimod data presentation at ASCRS Annual Meeting. Scientific Advisory Board meeting and Urcosimod data presentation at ASCRS boost pipeline visibility and expert input without transformative breakthroughs.

OKYO Pharma reported improved quality-of-life outcomes from its mid-stage eye pain trial. Positive mid-stage trial results advance OKYO's eye pain drug candidate and boost investor confidence.

OKYO Pharma reported new Phase 2 data showing Urcosimod delivers meaningful improvements in patient-reported quality of life outcomes for neuropathic corneal pain. Positive Phase 2 results for Urcosimod strengthen OKYO's clinical pipeline and boost investor sentiment toward potential commercialization.

OKYO Pharma Limited's abstract selected for presentation at premier global ophthalmology congress. Abstract selection at premier congress boosts OKYO's research credibility, visibility, and investor sentiment significantly.

OKYO Pharma to present first-in-human data for urcosimod at ARVO 2026. Presentation of first-in-human data at ARVO 2026 advances OKYO's pipeline and boosts visibility but remains early-stage with limited immediate financial impact.

OKYO Pharma garners bullish analyst sentiment after FDA endorses its Phase 2b/3 trial for treating neuropathic corneal pain. FDA endorsement of Phase 2b/3 trial marks a major regulatory milestone advancing OKYO toward potential drug approval and boosting market performance.

OKYO Pharma Limited has priced a $20 million public offering of its American Depositary Shares (ADS) to fund a late-stage clinical trial for its eye drug, OK-101. The offering is expected to close on November 1, 2023, with the company planning to use the proceeds primarily for the trial and general corporate purposes. The offering includes a 30-day option for underwriters to purchase additional ADSs. The company aims to advance its treatment for dry eye disease, which is currently in Phase 2b trials. The funding will significantly support the late-stage trial of a key product, potentially impacting the company's future performance and market position.

OKYO Pharma Limited announced the pricing of a public offering of ordinary shares, raising $20 million. The offering is expected to enhance the company's financial position and support its ongoing development initiatives. The shares will be offered at a price of $0.50 each, with the offering expected to close on or about October 30, 2023, subject to customary closing conditions. The public offering is likely to provide necessary funding for development but may not significantly alter the company's overall trajectory.

OKYO Pharma Limited has announced a public offering of ordinary shares to raise capital. The company aims to use the proceeds for general corporate purposes, including funding its ongoing clinical trials and research initiatives. The offering is expected to enhance the company's financial position and support its strategic objectives. The public offering may provide necessary funding for clinical trials, impacting financial performance and operational capabilities.

OKYO Pharma Limited has appointed Leerink Partners as the sales agent for its at-the-market (ATM) equity offering. This move is part of the company's strategy to raise capital through the sale of its American Depositary Receipts (ADRs) in the market. The appointment of a sales agent for an equity offering may influence financial performance and market sentiment but is not expected to fundamentally alter the company's trajectory.

OKYO Pharma Limited has announced the transition of its At-The-Market (ATM) equity offering facility to Leerink Partners. This strategic move is aimed at enhancing the company's capital-raising capabilities and improving its financial flexibility. The transition is expected to facilitate the company's ongoing efforts in advancing its clinical programs and overall business objectives. The transition to Leerink Partners may moderately influence OKYO's financial performance and market sentiment.

OKYO Pharma Limited has appointed Flavio Mantelli, MD, PhD, as its new Chief Medical Officer. Mantelli brings extensive experience in drug development and clinical research, having held leadership roles in various pharmaceutical companies. His appointment is expected to enhance OKYO's capabilities in advancing its pipeline of therapeutics, particularly in the field of ocular diseases. The appointment of a highly qualified CMO is likely to significantly impact the company's strategic direction and product development efforts.

OKYO Pharma Limited has appointed Flavio Mantelli as its new Chief Medical Officer. Mantelli brings extensive experience in drug development and clinical research, having held senior roles in various pharmaceutical companies. His appointment is expected to enhance OKYO's strategic direction and bolster its clinical programs. The appointment of a new Chief Medical Officer may influence the company's clinical development and operational strategy.

OKYO Pharma Limited announced that the results of its Phase 2 study for Urcosimod have been accepted for presentation at the ASCRS Annual Meeting, highlighting the company's progress in developing this treatment. The acceptance of study results for presentation at a prestigious conference indicates significant advancements in product development that could enhance investor sentiment and market positioning.

OKYO Pharma Limited has successfully cleared a crucial FDA meeting for its Urcosimod Phase 2b/3 trial, marking a significant step forward in the development of this treatment. The company aims to advance its clinical program, which could have implications for its future product offerings and market position. Clearing the FDA meeting is a significant regulatory milestone that could greatly influence the company's future performance and investor sentiment.

OKYO Pharma Limited announced a successful Type C meeting with the FDA, which is a significant step in the regulatory process for its drug development. The meeting provided clarity on the FDA's expectations and requirements for advancing their clinical programs, potentially accelerating the timeline for future submissions and approvals. The successful Type C meeting with the FDA is likely to significantly impact OKYO's regulatory strategy and future product development.

The FDA has approved the compassionate use of Urcosimod (0.05%) for treating neuropathic corneal pain, a significant development for OKYO Pharma Limited. This approval allows for the use of the drug in patients suffering from this condition, potentially expanding its market reach and providing relief to those affected. The FDA approval represents a significant regulatory milestone that could enhance product adoption and market presence.

OKYO Pharma Limited's intrinsic value is estimated to be 90% higher than its current share price, suggesting significant upside potential for investors. Analysts highlight the company's promising pipeline and recent developments that could enhance its market position. The valuation indicates that the stock may be undervalued, presenting an attractive investment opportunity for those looking to capitalize on future growth. The significant discrepancy between intrinsic value and share price indicates potential for major strategic moves and shifts in investor sentiment.

OKYO Pharma Limited has appointed Robert J. Dempsey as its new Chief Executive Officer. Dempsey brings extensive experience in the pharmaceutical industry, having held various leadership roles. His appointment is expected to guide the company in its strategic initiatives and enhance its operational capabilities. The appointment of a seasoned CEO may positively influence the company's strategic direction and operational efficiency.

OKYO Pharma Limited announced that its Chairman and Founder has acquired additional shares of the company, signaling confidence in its future prospects. This acquisition may influence investor sentiment and reflects the leadership's commitment to the company's growth. The share acquisition by the Chairman indicates a moderately noticeable influence on market sentiment and investor confidence.

OKYO Pharma Limited announced new data from its Phase 2 study indicating favorable outcomes for corneal nerve health in patients suffering from neuropathic corneal pain. The results suggest potential advancements in treatment options for this condition, highlighting the company's ongoing commitment to addressing unmet medical needs in ophthalmology. The positive Phase 2 study results could significantly enhance OKYO's product pipeline and market positioning in the ophthalmic sector.

OKYO Pharma Limited's Chairman and Founder has acquired additional shares of the company, signaling confidence in its future prospects. This acquisition may influence investor sentiment and reflects the leadership's commitment to the company's growth. Insider share acquisitions can positively affect market sentiment and indicate confidence in the company's future.